James Flynn's most recent trade in Larimar Therapeutics Inc was a trade of 3,387,539 Common Stock done at an average price of $3.2 . Disclosure was reported to the exchange on July 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Larimar Therapeutics Inc | Flynn E James | Director, Ten Percent Owner, * Director by Deputization | Purchase of securities on an exchange or from another person at price $ 3.20 per share. | 31 Jul 2025 | 3,387,539 | 9,538,945 | - | 3.2 | 10,840,125 | Common Stock |
| Larimar Therapeutics Inc | Flynn E James | Director, Ten Percent Owner, * Director by Deputization | Purchase of securities on an exchange or from another person at price $ 3.20 per share. | 31 Jul 2025 | 3,387,529 | 9,538,918 | - | 3.2 | 10,840,093 | Common Stock |
| Larimar Therapeutics Inc | Flynn E James | Director, Ten Percent Owner, * Director by Deputization | Purchase of securities on an exchange or from another person at price $ 3.20 per share. | 31 Jul 2025 | 2,599,932 | 7,321,129 | - | 3.2 | 8,319,782 | Common Stock |
| MEI Pharma Inc | James Flynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2025 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 8,128 | 24,830 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 8,128 | 0 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Sale of securities on an exchange or to another person at price $ 43.30 per share. | 30 Jun 2025 | 5,300 | 15,427 (0%) | 0% | 43.3 | 229,506 | Class A Common |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.63 per share. | 30 Jun 2025 | 4,103 | 20,727 (0%) | 0% | 44.6 | 183,117 | Class A Common |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 12,337 | 12,337 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 8,128 | 8,128 | - | - | Restricted Stock Units | |
| Lument Finance Trust Inc | James P. Flynn | CEO | Grant, award, or other acquisition of securities at price $ 21.49 per share. | 27 May 2025 | 230 | 905 | - | 21.5 | 4,943 | 7.875% Series A Cumulartive Redeemable Preferred Stock |
| Lument Finance Trust Inc | James P. Flynn | CEO | Grant, award, or other acquisition of securities at price $ 21.45 per share. | 23 May 2025 | 175 | 675 | - | 21.5 | 3,754 | 7.875% Series A Cumulartive Redeemable Preferred Stock |
| Lument Finance Trust Inc | James P. Flynn | CEO | Grant, award, or other acquisition of securities at price $ 21.50 per share. | 20 May 2025 | 175 | 500 | - | 21.5 | 3,763 | 7.875% Series A Cumulartive Redeemable Preferred Stock |
| Lument Finance Trust Inc | James P. Flynn | CEO | Grant, award, or other acquisition of securities at price $ 2.52 per share. | 16 May 2025 | 15,000 | 313,220 (1%) | 0% | 2.5 | 37,790 | common stock |
| Lument Finance Trust Inc | James P. Flynn | CEO | Grant, award, or other acquisition of securities at price $ 2.49 per share. | 16 May 2025 | 10,719 | 323,939 (1%) | 0% | 2.5 | 26,684 | common stock |
| Lument Finance Trust Inc | James P. Flynn | CEO | Grant, award, or other acquisition of securities at price $ 22.00 per share. | 16 May 2025 | 175 | 325 | - | 22 | 3,850 | 7.875% Series A Cumulative Redeemable Preferred Stock |
| Lument Finance Trust Inc | James P. Flynn | CEO | Grant, award, or other acquisition of securities at price $ 21.96 per share. | 16 May 2025 | 150 | 150 | - | 22.0 | 3,294 | 7.875% Series A Cumulartive Redeemable Preferred Stock |
| Larimar Therapeutics Inc | Flynn E James | Director, Ten Percent Owner, * Director by Deputization | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2025 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.64 per share. | 30 Apr 2025 | 4,402 | 16,702 (0%) | 0% | 43.6 | 192,103 | Class A Common |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 3,330 | 17,852 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 3,330 | 6,659 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 3,252 | 9,759 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 3,252 | 21,104 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 1,557 | 14,522 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 1,557 | 1,557 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 625 | 12,965 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 625 | 0 | - | - | Restricted Stock Units | |
| Synlogic Inc | James Flynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2025 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 3,185 | 14,102 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 3,185 | 0 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.69 per share. | 01 Jul 2024 | 1,762 | 12,340 (0%) | 0% | 40.7 | 71,696 | Class A Common |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 13,011 | 13,011 | - | - | Restricted Stock Units | |
| Larimar Therapeutics Inc | Flynn E James | Director, Ten Percent Owner, * Director by Deputization | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 3,185 | 3,185 | - | - | Restricted Stock Units | |
| MEI Pharma Inc | James Flynn | Director | 16 May 2024 | 7,900 | 7,900 (0%) | 0% | 3.2 | 24,981 | Common Stock | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.57 per share. | 30 Apr 2024 | 3,594 | 10,917 (0%) | 0% | 37.6 | 135,027 | Class A Common |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 3,329 | 14,511 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 3,329 | 9,989 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 1,557 | 11,182 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 1,557 | 3,114 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 932 | 0 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 932 | 9,001 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 624 | 625 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 624 | 9,625 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Sale of securities on an exchange or to another person at price $ 38.82 per share. | 10 Apr 2024 | 6,114 | 8,069 (0%) | 0% | 38.8 | 237,345 | Class A Common |
| Synlogic Inc | James Flynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2024 | 4,000 | 4,000 | - | - | Stock Option (right to buy) | |
| Larimar Therapeutics Inc | Flynn James E | Director, Ten Percent Owner, * Director by Deputization | Purchase of securities on an exchange or from another person at price $ 8.74 per share. | 16 Feb 2024 | 1,430,206 | 6,151,389 | - | 8.7 | 12,500,000 | Common Stock |
| Larimar Therapeutics Inc | James Flynn E | Director, Ten Percent Owner, * Director by Deputization | Purchase of securities on an exchange or from another person at price $ 8.74 per share. | 16 Feb 2024 | 1,430,206 | 6,151,406 | - | 8.7 | 12,500,000 | Common Stock |
| Larimar Therapeutics Inc | E Flynn James | Director, Ten Percent Owner, * Director by Deputization | Purchase of securities on an exchange or from another person at price $ 8.74 per share. | 16 Feb 2024 | 1,430,205 | 4,207,982 | - | 8.7 | 12,499,992 | Common Stock |
| Oruka Therapeutics Inc | Flynn James | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| MEI Pharma Inc | Flynn James | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| MEI Pharma Inc | James Flynn | Director | 18 Dec 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | ||
| MEI Pharma Inc | James Flynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 6,700 | 6,700 | - | - | Stock Options (Right to Buy) | |
| MEI Pharma Inc | James Flynn | Director | 18 Dec 2023 | 6,700 | 6,700 | - | - | Stock Option (Right to Buy) | ||
| John Wiley Sons Inc Ordinary | James J. Flynn | EVP & GM, Research & Learning | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2023 | 20,000 | 20,000 | - | - | Non-Qualified Stock Options (right to buy) | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 6,617 | 0 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 6,617 | 16,850 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.03 per share. | 30 Jun 2023 | 2,667 | 14,183 (0%) | 0% | 34.0 | 90,758 | Class A Common |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 13,318 | 13,318 | - | - | Restricted Stock Units | |
| Larimar Therapeutics Inc | Flynn James E | Director, Ten Percent Owner, * Director by Deputization | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2023 | 8,300 | 8,300 | - | - | Stock Option (Right to Buy) | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 1,556 | 4,671 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 1,556 | 11,789 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.21 per share. | 01 May 2023 | 1,556 | 10,233 (0%) | 0% | 38.2 | 59,455 | Class A Common |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 931 | 932 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 931 | 9,608 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 742 | 0 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 742 | 8,677 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 625 | 1,249 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 625 | 10,233 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2023 | 10,338 | 0 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2023 | 10,338 | 12,293 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.60 per share. | 09 Jan 2023 | 4,358 | 7,935 (0%) | 0% | 42.6 | 185,651 | Class A Common |
| Oruka Therapeutics Inc | James Flynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 6,227 | 9,919 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 3,692 | 3,692 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.15 per share. | 02 May 2022 | 1,069 | 1,629 (0%) | 0% | 50.1 | 53,610 | Class A Common |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 931 | 931 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 931 | 5,686 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 741 | 1,672 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 741 | 742 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 624 | 1,874 | - | - | Restricted Stock Units | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 624 | 2,296 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 402 | 2,698 (0%) | 0% | 0 | Class A Common | |
| John Wiley Sons Inc Ordinary | James Flynn J. | EVP and GM, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 402 | 0 | - | - | Restricted Stock Units | |
| Lument Finance Trust Inc | James P. Flynn | CEO | Purchase of securities on an exchange or from another person at price $ 2.82 per share. | 21 Mar 2022 | 13,500 | 298,220 (1%) | 0% | 2.8 | 38,081 | common stock |
| Lument Finance Trust Inc | James P. Flynn | CEO | 11 Feb 2022 | 177,540 | 0 | - | - | Subscription Rights (right to buy) | ||
| Lument Finance Trust Inc | James P. Flynn | CEO | 11 Feb 2022 | 177,540 | 284,720 (1%) | 0% | 3.1 | 543,272 | Common Stock |